Developing drugs of a new class for the treatment against obesity and metabolic syndromes: synthesis of chemical compounds that inhibit ARIA

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670406
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Cardiovascular medicine
• Research Institution: Kobe Pharmaceutical University
• Principal Investigator: IKEDA KOJI 神戸薬科大学, 薬学部, 准教授 (90423871)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 肥満 / メタボリック症候群 / 脂肪血管新生 / ARIA

Outline of Final Research Achievements

ARIA-KO mice were resistant against obesity and obesity-related metabolic syndromes. We previously identified a compound (C30) that inhibits ARIA function. Here we analyzed effects of compounds structurally related to C30 on ARIA functions. We picked up 70 compounds and analyzed their inhibitory effect on ARIA. Four C30-like compounds practically inhibited ARIA function, and they all contain the same basic structure. However, these four compounds showed less inhibitory effect on ARIA function comparing to C30, while they showed lower cytotoxicity than C30.
We then tried to establish a new assay method for compound screening for ARIA-inhibitor, and constructed cell free alpha-screening system that could detect inhibitory effect of compounds against ARIA.

Free Research Field

血管生物学